CN102985095B - 免疫刺激组合物和疫苗组合物 - Google Patents

免疫刺激组合物和疫苗组合物 Download PDF

Info

Publication number
CN102985095B
CN102985095B CN201180033660.4A CN201180033660A CN102985095B CN 102985095 B CN102985095 B CN 102985095B CN 201180033660 A CN201180033660 A CN 201180033660A CN 102985095 B CN102985095 B CN 102985095B
Authority
CN
China
Prior art keywords
mannan
composition
kda
antigen
oxidized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180033660.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102985095A (zh
Inventor
G.A.彼得斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Moral Biology Pharmacy Co Ltd Of Essen
Original Assignee
Moral Biology Pharmacy Co Ltd Of Essen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010901997A external-priority patent/AU2010901997A0/en
Application filed by Moral Biology Pharmacy Co Ltd Of Essen filed Critical Moral Biology Pharmacy Co Ltd Of Essen
Publication of CN102985095A publication Critical patent/CN102985095A/zh
Application granted granted Critical
Publication of CN102985095B publication Critical patent/CN102985095B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201180033660.4A 2010-05-10 2011-05-10 免疫刺激组合物和疫苗组合物 Expired - Fee Related CN102985095B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US33308610P 2010-05-10 2010-05-10
AU2010901997 2010-05-10
US61/333,086 2010-05-10
AU2010901997A AU2010901997A0 (en) 2010-05-10 Immunostimulatory and vaccine compositions
AU2010904060A AU2010904060A0 (en) 2010-09-09 Immunostimulatory and vaccine compositions
AU2010904060 2010-09-09
PCT/AU2011/000542 WO2011140595A2 (en) 2010-05-10 2011-05-10 Immunostimulatory and vaccine compositions

Publications (2)

Publication Number Publication Date
CN102985095A CN102985095A (zh) 2013-03-20
CN102985095B true CN102985095B (zh) 2016-05-18

Family

ID=44914748

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180033660.4A Expired - Fee Related CN102985095B (zh) 2010-05-10 2011-05-10 免疫刺激组合物和疫苗组合物

Country Status (9)

Country Link
US (1) US9597392B2 (https=)
EP (1) EP2574170A4 (https=)
JP (1) JP6096111B2 (https=)
CN (1) CN102985095B (https=)
AU (1) AU2011226992B2 (https=)
BR (1) BR112012028893A2 (https=)
CA (1) CA2798856C (https=)
RU (1) RU2578420C2 (https=)
WO (1) WO2011140595A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2725450T3 (es) 2007-07-02 2019-09-24 Etubics Corp Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
IN2014CN04251A (https=) * 2011-11-09 2015-07-17 Ascend Biopharmaceuticals Ltd
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
ES2503516B1 (es) * 2013-04-03 2015-09-09 Inmunotek, S.L. Complejo inmunogénico para vacunación y método de obtención
CA2973109A1 (en) 2015-01-09 2016-07-14 Etubics Corporation Methods and compositions for ebola virus vaccination
KR102193635B1 (ko) 2015-01-09 2020-12-21 이투빅스 코포레이션 복합 면역요법을 위한 방법 및 조성물
WO2016172249A1 (en) * 2015-04-20 2016-10-27 Etubics Corporation Methods and compositions for combination immunotherapy
JP7084881B2 (ja) 2016-06-22 2022-06-15 アルカームス インコーポレーテッド Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法
FI3833378T3 (fi) 2018-08-06 2025-06-16 Nielsen Biosciences Inc Syylien hoito
US11197910B1 (en) * 2020-08-19 2021-12-14 Vitruviae LLC Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases
EP4304606A4 (en) * 2021-03-12 2025-08-20 Childrens Medical Center POLYSACCHARIDE-BASED ADJUVANTS FOR VIRUS VACCINES
CN113616799B (zh) * 2021-07-13 2023-08-29 中国科学院长春应用化学研究所 一种疫苗载体、其制备方法及应用
JPWO2024117232A1 (https=) * 2022-11-30 2024-06-06

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3362951A (en) 1965-12-21 1968-01-09 Farkas Alexander Polysaccharide product derived from the juice of the aloe plant and methods for preparing same
US4735935A (en) 1985-12-17 1988-04-05 Carrington Laboratories, Inc. Process for preparation of aloe products products, produced thereby and compositions thereof
US5308838A (en) 1982-05-07 1994-05-03 Carrington Laboratories, Inc. Uses of aloe products
US4861761A (en) 1984-06-28 1989-08-29 Dr. Madis Laboratories, Inc. Aloeferon isolation, manufacturing and its applications
FR2573656B1 (fr) * 1984-11-29 1987-02-27 Sanofi Sa Medicament comportant en tant qu'association au moins une immunotoxine et au moins un polymere contenant du mannose
EP0823438A3 (en) 1987-01-07 1999-09-15 Imperial Cancer Research Technology Limited Human mucin cone protein: peptide fragments and antibodies thereto, and uses thereof in diagnostic and therapeutic methods
US6222020B1 (en) 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
ATE475668T1 (de) 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
US5939400A (en) 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
US6110898A (en) 1996-05-24 2000-08-29 University Of Maryland, Baltimore DNA vaccines for eliciting a mucosal immune response
US5824659A (en) 1996-09-04 1998-10-20 Board Of Regents, The University Of Texas System Cytoprotective oligosaccharide from Aloe preventing damage to the skin immune system by UV radiation
ATE341339T1 (de) 1996-12-20 2006-10-15 Merck & Co Inc Zusammensetzungen von rekombinanten papillomavirus vakzinen
ES2357960T3 (es) 1997-05-08 2011-05-04 Oncothyreon Inc. Procedimiento para generar células t activadas y células presentadoras de antígenos pulsadas con antígenos.
CA2329897A1 (en) 1998-04-28 1999-11-04 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
DE19917195B4 (de) 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
JP2003510094A (ja) 1999-09-08 2003-03-18 トランジェーヌ、ソシエテ、アノニム Ｍｕｃ−１由来のペプチド
EP1257565A4 (en) 2000-02-01 2005-04-06 Austin Research Inst DERIVED FROM MUCIN-1 ANTIGENE AND ITS USE IN IMMUNOTHERAPY
AUPQ797700A0 (en) * 2000-06-06 2000-06-29 Austin Research Institute, The Vaccine
WO2008037033A1 (en) * 2006-09-29 2008-04-03 The Macfarlane Burnet Institute For Medical Research And Public Health Limited Flu vaccine admixture of mannan and flu antigen
US7196072B2 (en) 2000-07-10 2007-03-27 University Of Mississippi High molecular weight polysaccharide fraction from Aloe vera with immunostimulatory activity
ATE265218T1 (de) * 2000-08-10 2004-05-15 Ocean Nutrition Canada Ltd Chlorella zubereitungen mit immunmodulatorischen eigenschaften
NZ538812A (en) 2002-08-15 2009-02-28 3M Innovative Properties Co Immunostimulatory compositions and methods of stimulating an immune response
AU2003256912A1 (en) 2002-08-16 2004-03-03 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
WO2005044861A1 (en) 2003-10-31 2005-05-19 Wyeth Holdings Corporation Polysaccharides of helicobacter pylori
EP1697515A4 (en) * 2003-11-12 2008-02-06 Austin Research Inst DNA CARRIER CONJUGATE
US20060084629A1 (en) 2004-10-15 2006-04-20 Alvin Needleman Immune system activating formula composed of selected long chain polysaccharides from natural sources
JP2006241023A (ja) * 2005-03-01 2006-09-14 Asahi Breweries Ltd 消化管組織における抗菌ペプチドの発現誘導または産生促進剤
JP2006241020A (ja) * 2005-03-01 2006-09-14 Asahi Breweries Ltd 免疫系賦活剤
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
ES2776100T3 (es) 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
JP2009544291A (ja) 2006-07-25 2009-12-17 フォージー ヴァクシンズ ピーティーワイ エルーティーディー ムチン１（ｍｕｃ１）ｔ細胞エピトープ由来ペプチド含有癌ワクチン
AU2007300543A1 (en) 2006-09-26 2008-04-03 Alexion Pharmaceuticals, Inc. Compositions and methods for enhancing an adjuvant
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway;Vasso Apostolopoulos等;《Eur. J. Immunol》;20001231;第30卷;1714-1723 *

Also Published As

Publication number Publication date
EP2574170A4 (en) 2013-11-20
JP2013527854A (ja) 2013-07-04
CA2798856C (en) 2019-04-23
BR112012028893A2 (pt) 2017-12-12
US20130251741A1 (en) 2013-09-26
AU2011226992A1 (en) 2011-11-24
JP6096111B2 (ja) 2017-03-15
RU2578420C2 (ru) 2016-03-27
AU2011226992B2 (en) 2012-03-22
EP2574170A2 (en) 2013-04-03
WO2011140595A2 (en) 2011-11-17
US9597392B2 (en) 2017-03-21
WO2011140595A3 (en) 2012-01-05
RU2012152952A (ru) 2014-06-20
CA2798856A1 (en) 2011-11-17
CN102985095A (zh) 2013-03-20

Similar Documents

Publication Publication Date Title
CN102985095B (zh) 免疫刺激组合物和疫苗组合物
AU2012334825B2 (en) Immunomodulatory conjugates
JP6825036B2 (ja) 免疫応答のプライミング
JP2000506125A (ja) 免疫調節のための医薬組成物
CN101678091A (zh) 冷冻干燥的抗原组合物
US12478669B1 (en) Herpes zoster mRNA vaccine, preparation method therefor, and use thereof
JP2009524584A (ja) ポリマー−生物製剤送達組成物を構築するための方法
JP6165182B2 (ja) 免疫アジュバントとしてのグリコシル化により改変された四官能性非イオン性両親媒性ブロックコポリマーの使用
CN118340879B (zh) 复合佐剂、含佐剂的抗肿瘤疫苗、复合佐剂抗肿瘤疫苗及其制备方法与应用
Zhou et al. Multifunctional lipidated protein carrier with a Built-In adjuvant as a universal vaccine platform potently elevates immunogenicity of weak antigens
KR20140099828A (ko) 점막 투여용 백신 조성물
Kikuchi Genetically modified dendritic cells for therapeutic immunity
JP7387439B2 (ja) 改良されたｌｉワクチンアジュバント
Tang et al. Oxidized and reduced mannan mediated MUC1 DNA immunization induce effective anti-tumor responses
Pappalardo et al. Characterization of a nanovaccine platform based on an α1, 2-mannobiose derivative shows species-non-specific targeting to human, bovine, mouse, and teleost fish dendritic cells
JP2005506315A (ja) コレラ毒素およびそのｂサブユニットを用いた抗原提示を促進し免疫応答をモジュレートするための方法
Lin et al. Co-delivery of PSMA antigen epitope and mGM-CSF with a cholera toxin-like chimeric protein suppressed prostate tumor growth via activating dendritic cells and promoting CTL responses
AU2012200183B2 (en) Immunostimulatory and vaccine compositions
EP3473641A1 (en) Nucleic acid-antigen peptide conjugate
JP2022036961A (ja) 樹状細胞療法においてｅｘ ｖｉｖｏでの抗原のプロセシングと提示を亢進させるための合成ベクターとしての脂質
TWI916817B (zh) 一種針對ＭＩＣＡ/Ｂ靶點的ｍＲＮＡ腫瘤疫苗
US8921534B2 (en) Enhancement of the immune response using CD36-binding domain
WO2026034613A1 (ja) ｍＲＮＡワクチンアジュバント
WO2026005699A1 (en) Immunogenic constructs for protein-based adjuvantation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160518

Termination date: 20200510

CF01 Termination of patent right due to non-payment of annual fee